{"id":"en3270","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EN3270 works by binding to the sigma-1 receptor, which is involved in various cellular processes. This binding leads to a cascade of downstream effects that ultimately result in the therapeutic effect of the drug.","oneSentence":"EN3270 is a small molecule that targets the sigma-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:29.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"}]},"trialDetails":[{"nctId":"NCT00485225","phase":"PHASE2","title":"Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain","status":"COMPLETED","sponsor":"Durect","startDate":"2007-06","conditions":"Chronic, Non Malignant Pain","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EN3270","genericName":"EN3270","companyName":"Durect","companyId":"durect","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EN3270 is a small molecule that targets the sigma-1 receptor. Used for Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}